Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience
The Oncologist · 06.06.2026 · 31 (7)
DOI: 10.1093/oncolo/oyag220 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 02.06.2026. Verfasst von Riham Suleiman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Hauptthemen laut MEDLINE: Paget Disease, Extramammary, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma. While localized disease has an excellent prognosis, metastatic EMPD is aggressive with no standardized systemic therapy. This study characterizes the clinicopathologic and molecular landscape of metastatic/recurrent EMPD to identify therapeutic vulnerabilities. Patients and methods We conducted a retrospective cohort study of 26 patients with metastatic or distantly recurrent EMPD treated at Mayo Clinic (2000-2025). Descriptive statistics were used to summarize baseline characteristics. Survival outcomes were estimated using Kaplan–Meier methods, with group comparisons performed using log-rank testing. Continuous variables were compared using nonparametric tests, and categorical variables were analyzed using appropriate comparative tests. Pathway-level genomic correlations with TCGA reference cohorts were assessed using Spearman rank correlation. Treatment responses were retrospectively evaluated from radiologic reports.
Results
The cohort was predominantly male (73.1%) and White (92.3%), with a median age of 68 (IQR, 53-79). Lymph nodes were the most common metastatic site (61.5%). The median overall survival (OS) was 20.0 months (95% CI, 0-40.4). IHC showed universal CK7 and GATA3 positivity, with 80% androgen receptor (AR) expression. HER2 was positive (3+) or amplified in approximately one-third of cases. NGS revealed frequent mutations in TP53 (68.8%), ERBB2 (50%), and CDKN2A/B (50%). A “triple-hit” deletion at the 9p21 locus (CDKN2A/B/MTAP) was identified in 25% of cases. Genomic profiling showed strong similarity to HER2+ breast and urothelial carcinomas. HER2-directed therapy was associated with longer overall survival (median OS 73.0 months [95% CI, 0-177.9] vs 19.0 months [95% CI, 0-41.4]; HR 0.50 [95% CI, 0.0-177.9], P = .3), although this difference did not reach statistical significance.
Conclusion
Metastatic EMPD exhibits distinct clinicopathologic and molecular features, including high AR and HER2 expression, TP53 and CDKN2A/B alterations, and similarity to systemic HER2+ malignancies. The observed activity of HER2-directed therapies in this cohort suggests the potential value of further investigating biomarker-guided treatment strategies in metastatic EMPD. NGS-guided profiling may inform precision treatment strategies, including AR-targeted therapy and emerging MTAP-directed approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL 32224, United States.
- Department of Dermatology, Division of Dermatologic Surgery, Mayo Clinic, Rochester, MN 55905, United States.
ORCID-Profile: Riham Suleiman, Harry E Fuentes Bayne
Zitieren
APA
Suleiman, R., Guo, R., Lohman, M. E., Thome, S. D., Pagliaro, L. C., Markovic, S. N., Halfdanarson, T. R., & Fuentes Bayne, H. E. (2026). Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag220
Vancouver
Suleiman R, Guo R, Lohman ME, Thome SD, Pagliaro LC, Markovic SN, et al. Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag220
BibTeX
@article{Suleiman2026,
author = {Suleiman, Riham and Guo, Ray and Lohman, Mary E and Thome, Stephan D and Pagliaro, Lance C and Markovic, Svetomir N and Halfdanarson, Thorvardur R and Fuentes Bayne, Harry E},
title = {Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {7},
doi = {10.1093/oncolo/oyag220}
}
EUVIMED